You are here

Novel Therapeutic Targets for Parkinson's disease

Description 
Parkinson's disease (PD) is a debilitating neurodegenerative disorder that affects over 7 million people worldwide. Hallmark symptom of PD is the inability to initiate and maintain voluntary movement which results from the loss of midbrain dopamine neurons. Current PD therapies (e.g. levodopa) only relieve the symptoms but do not modify the disease progression. The current project aims to identify and characterize (i) novel therapeutic targets to slow or halt the progression of PD and (ii) novel sex-specific targets for neuroprotection or symptomatic relief in PD. Approaches include toxin- and genetic-based animal models of Parkinson’s diseases, stereotaxic neurosurgery, intracerebral drug administration, assessment of rodent behaviour, analysis of post-mortem PD patient brain tissue, pateneuroanatomy, qRT-PCR, immunohistochemistry, and electrophysiology.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Dopamine, Substantia nigra, Neuroprotection, Pre-symptomatic, Sry, Neurotransmitter
School 
Available options 
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Graduate Diploma
Short projects
Joint PhD/Exchange Program
Time commitment 
Full-time
Part-time
Top-up scholarship funding available 
No
Physical location 
Monash Health Translation Precinct (Monash Medical Centre)
Co-supervisors 
Prof 
Dominic Thyagarajan

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.